Regencell Bioscience Holdings Ltd(RGC)Stock Analysis

RGC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Regencell Bioscience Holdings Ltd (RGC), a Healthcare sector company. RGC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), Regencell Bioscience Holdings Ltd reports net income of $-3.6M, free cash flow of $-3.3M. Top institutional holders of RGC by reported 13-F value include GEODE CAPITAL MANAGEMENT,, SUSQUEHANNA INTERNATIONAL GROUP, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. RGC trades on the Nasdaq exchange and files with the SEC under CIK 1829667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RGC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Regencell Bioscience Holdings Ltd directly from SEC EDGAR.